Plasma medicine: cells, blood & tissue

Immune Cells Enhance Selectivity of Nanosecond-Pulsed DBD Plasma Against Tumor Cells

A. Lin, B. Truong, G. Fridman, A. A. Fridman, V. Miller

Plasma Medicine, 2017, 7(1): 85–96
DOI: 10.1615/PlasmaMed.2017019666 (opens in a new tab) Cited by 28

Abstract

Cancer immunotherapy is a promising strategy that engages the patient’s immune system to kill cancer cells selectively while sparing normal tissue. Treatment of macrophages with a nanosecond-pulsed dielectric barrier discharge directly enhanced their cytotoxic activity against tumor cells but not normal cells. These results underscore the clinical potential of plasma for cancer immunotherapy.

How to cite

A. Lin, B. Truong, G. Fridman, A. A. Fridman, V. Miller (2017). Immune Cells Enhance Selectivity of Nanosecond-Pulsed DBD Plasma Against Tumor Cells. Plasma Medicine, 7(1): 85–96. https://doi.org/10.1615/PlasmaMed.2017019666